Chemical screening of novel factor to promote beta cell differentiation from hiPS cells
Project/Area Number |
25505003
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Regenerative medicine
|
Research Institution | Saitama Medical University |
Principal Investigator |
|
Co-Investigator(Renkei-kenkyūsha) |
Matsumoto Masahito 埼玉医科大学, 医学部, 講師 (90321819)
|
Research Collaborator |
Sugahara Yzumi (Yamashita Yzumi) 埼玉医科大学, 医学部, 研究員 (10633000)
|
Project Period (FY) |
2013-04-01 – 2016-03-31
|
Project Status |
Completed (Fiscal Year 2015)
|
Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2015: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2014: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2013: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
Keywords | 膵β細胞分化 / hiPSレポーター / ケミカルスクリーニング / β細胞 / single cell / double KI hiPSC / iPS細胞 / 膵β細胞 / 化合物スクリーニング |
Outline of Final Research Achievements |
Human induced pluripotent stem (hiPS)cells are an ideal resource for the cell based therapy. In this sense, the beta cell production by hiPS cells is a prominent therapeutic method to replenish the beta cells that are destroyed in type I diabetes. However, the efficiency and the quality of the beta cells produced from hiPS cells are not sufficient for cell therapy. The aim of this study is to improve the pancreatic beta cell differentiation from hiPS cells by screening with the chemical library. We found that the FGFR1 specific inhibitor C8 augmented the beta cell differentiation by improving the glucose responsivity and expression of the mRNA genes related to insulin releasing procedure, such as GCK, SlC30A8 and GLP1R.
|
Report
(4 results)
Research Products
(1 results)